The addition of T2A to Quintiles' product commercialization service group, Innovex, significantly enhances Innovex's capabilities in France and strengthens its ability to provide comprehensive contract sales services across Europe.

Quintiles acquired T2A in exchange for Quintiles stock in a pooling of interests transaction that is expected to be neutral to slightly accretive to Quintiles' earnings per share. T2A is a privately held company based in Paris.

"T2A's strong management, established customer base and superior service makes it an excellent addition to Innovex's European sales network," said David White, Innovex CEO. "We now can provide our customers in France with a unique combination of local sales knowledge and presence, and coordinated pan-European or global commercialization programs. This is the latest example of a strategy we have developed worldwide to meet our customers' needs."

With $20 billion a year in sales, the French pharmaceutical market trails only the United States, Japan and Germany.

T2A will be combined with Innovex's existing operations in France and do business as Innovex France. Quintiles has entered into employment agreements with T2A senior managers, including Pierre Olhagaray as president of Innovex France; Bruno Baufle as head of sales and marketing; and Pierre Mancuso as head of finance and administration. Peter Payne, the current head of Innovex's business in France, will continue as head of Innovex Clinical Research and Health Management Services.

"Being a part of Quintiles and Innovex means we can offer our customers a wider range of services," Olhagaray said. "T2A has had great success since its founding in 1979 by Roger Gravier du Monceau, and we look forward to even greater success in the months and years to come."

T2A's office in Paris is located at 2 rue Cepre, Paris, France, phone +33 1 4061 7777, fax +33 1 4783 8222.

The addition of More Biomedical establishes Quintiles as the leading provider of CRO services in the growing Taiwanese market. Based in Taipei, More Biomedical provides clinical research services to both Taiwanese and international pharmaceutical companies. A privately held company with 10 employees, More Biomedical was acquired in exchange for Quintiles stock in a pooling of interests transaction that is expected to be neutral to Quintiles' earnings per share.

More Biomedical will operate as Quintiles Taiwan, a part of Quintiles CRO, and be managed by Ray Wang, who founded More Biomedical in 1994. The office will remain at its current location at 3F, Sec.3, Chuan-Shan N. Road, Taipei, 104 Taiwan. Phone +886-22-595 3415.

Quintiles Transnational Corp. is the market leader in providing full-service contract research, sales andmarketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries. Quintiles is headquartered near Research Triangle Park, North Carolina. With 10,000 employees worldwide and offices in 26 countries, Quintiles operates through specialized work groups dedicated to meeting individual customer needs.

Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the ability of the combined businesses to be integrated with Quintiles' current operations, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, and the actual costs of combining the businesses. Additional factors that could cause actual results to differ materially are discussed in the company's recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports.